Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRCP | P42785 | 11/20 | 0.64 |
| ▸ | HPGDS | O60760 | 3/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.56 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.56 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.56 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.56 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.56 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.54 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10145019 | 1.00 | PRCP (0.64) | PRCPHPGDSCYP3A4CYP2C9NR1I2 | |
| SCHEMBL4957215 | 0.98 | HPGDS (0.62) | PRCPHPGDSCYP3A4CYP2C9NR1I2 | |
| SCHEMBL4957220 | 0.98 | HPGDS (0.62) | PRCPHPGDSCYP3A4CYP2C9NR1I2 | |
| SCHEMBL15277177 | 0.98 | HPGDS (0.62) | PRCPHPGDSCYP3A4CYP2C9NR1I2 | |
| SCHEMBL753302 | 0.96 | CYP3A4 (0.60) | PRCPHPGDSCYP3A4CYP2C9NR1I2 | |
| SCHEMBL11910995 | 0.96 | CYP3A4 (0.60) | PRCPHPGDSCYP3A4CYP2C9NR1I2 | |
| SCHEMBL2706110 | 0.95 | CYP3A4 (0.58) | PRCPHPGDSCYP3A4CYP2C9NR1I2 | |
| SCHEMBL19789918 | 0.94 | CYP3A4 (0.58) | PRCPHPGDSCYP3A4CYP2C9NR1I2 | |
| SCHEMBL12158444 | 0.93 | PRCP (0.60) | PRCPHPGDSCYP3A4CYP2C9NR1I2 | |
| SCHEMBL13223842 | 0.92 | PRCP (0.55) | PRCPHPGDSCYP3A4CYP2C9NR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9932326-B2 | Potent and selective inhibitors of hepatitis C virus | Cocrystal Pharma, LLC (US) | 2018-04-03 | — | — | US | disclosed |
| CN-103977406-B | Antiviral compound | 吉利德制药有限责任公司 | 2016-10-19 | — | — | CN | disclosed |
| US-20160068518-A1 | POTENT AND SELECTIVE INHIBITORS OF HEPATITIS C VIRUS | EMORY UNIVERSITY | 2016-03-10 | — | — | US | disclosed |
| EP-2963034-A1 | POTENT AND SELECTIVE INHIBITORS OF HEPATITIS C VIRUS | RFS Pharma, LLC. (US) | 2016-01-06 | — | — | EP | disclosed |
| US-9181227-B2 | Potent and selective inhibitors of hepatitis C virus | COCRYSTAL PHARMA, INC. (US) | 2015-11-10 | — | — | US | disclosed |
| US-20140350016-A1 | POTENT AND SELECTIVE INHIBITORS OF HEPATITIS C VIRUS | EMORY UNIVERSITY | 2014-11-27 | — | — | US | disclosed |
| US-8859595-B2 | Potent and selective inhibitors of hepatitis C virus | RFS PHARMA, LLC (US) | 2014-10-14 | — | — | US | disclosed |
| US-20130210774-A1 | POTENT AND SELECTIVE INHIBITORS OF HEPATITIS C VIRUS | EMORY UNIVERSITY (US) | 2013-08-15 | — | — | US | disclosed |
| EP-2616461-A2 | POTENT AND SELECTIVE INHIBITORS OF HEPATITIS C VIRUS | RFS Pharma, LLC. (US) | 2013-07-24 | — | — | EP | disclosed |
| WO-2012027712-A2 | POTENT AND SELECTIVE INHIBITORS OF HEPATITIS C VIRUS | RFS PHARMA, LLC (US) | 2012-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160068518-A1 | POTENT AND SELECTIVE INHIBITORS OF HEPATITIS C VIRUS | HAVCR2, SLC10A1, PYGL | PRCP 48/4885HPGDS 858/4885CYP3A4 208/4885 |
| US-20130210774-A1 | POTENT AND SELECTIVE INHIBITORS OF HEPATITIS C VIRUS | HAVCR2, SLC10A1, PYGL | PRCP 48/4885HPGDS 858/4885CYP3A4 208/4885 |
| US-20140350016-A1 | POTENT AND SELECTIVE INHIBITORS OF HEPATITIS C VIRUS | HAVCR2, SLC10A1, PYGL | PRCP 48/4885HPGDS 858/4885CYP3A4 208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.